drugset
drugset / Trial / NCT02906397

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)

NCT02906397 ↗

Phase 1 Completed 15 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).

Timeline

Start
2017-03-30
Primary completion
2021-07-21
Completion
2021-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Galunisertib Small molecule 150 mg Oral

Indications

hepatocellular carcinoma